Related Experiment Video

Updated: Jun 19, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Adding more content to screening: reactivation of FOXO as a therapeutic strategy

Fabian Zanella1, Amancio Carnero

  • 1Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|October 16, 2009
PubMed

Insights

High-content screening (HCS) advances drug discovery by analyzing image-based assays. This review explores HCS platforms for identifying molecules that modulate FOXO nuclear relocation and activation, crucial for disease treatment.

Area of Science:

  • Biomedical research
  • Pharmacology
  • Drug discovery

Background:

  • High-throughput screening (HTS) enables rapid screening of numerous compounds or genes.
  • High-content screening (HCS) offers more comprehensive data through image-based assays compared to traditional HTS.
  • Identifying novel pharmacological targets is key to improving disease outcomes.

Purpose of the Study:

  • To review the development of High-content screening (HCS) platforms.
  • To explore the identification of molecules influencing FOXO nuclear relocation and activation.
  • To discuss the applicability and future directions of HCS in drug discovery.

Main Methods:

  • Review of existing literature on High-content screening (HCS) platform development.
  • Analysis of HCS applications in identifying modulators of FOXO signaling.
  • Discussion of technological advancements and future trends in screening methodologies.

Main Results:

  • HCS platforms provide richer, image-based data for complex biological insights.
  • FOXO nuclear relocation and activation are viable targets for pharmacological intervention.
  • The review highlights the potential of HCS in accelerating the discovery of novel therapeutic molecules.

Conclusions:

  • High-content screening (HCS) represents a significant advancement over traditional HTS for drug discovery.
  • Targeting FOXO pathways through HCS can lead to novel therapeutic strategies.
  • Continued development of HCS technology will further enhance the identification of drug candidates.

More Related Videos

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome11:15

Pooled shRNA Screen for Reactivation of MeCP2 on the Inactive X Chromosome

Published on: March 2, 2018

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...